- Home
- PACB vs KROS Comparison
PACB vs KROS Comparison
Compare PACB & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PACB
- KROS
- Stock Information
- Founded
- PACB 2000
- KROS 2015
- Country
- PACB United States
- KROS United States
- Employees
- PACB 575
- KROS N/A
- Industry
- PACB Biotechnology: Laboratory Analytical Instruments
- KROS Biotechnology: Pharmaceutical Preparations
- Sector
- PACB Industrials
- KROS Health Care
- Exchange
- PACB Nasdaq
- KROS Nasdaq
- Market Cap
- PACB 567.6M
- KROS 565.0M
- IPO Year
- PACB 2010
- KROS 2020
- Fundamental
- Price
- PACB $2.21
- KROS $17.50
- Analyst Decision
- PACB Buy
- KROS Buy
- Analyst Count
- PACB 6
- KROS 15
- Target Price
- PACB $2.00
- KROS $22.10
- AVG Volume (30 Days)
- PACB 10.1M
- KROS 1.2M
- Earning Date
- PACB 11-05-2025
- KROS 11-05-2025
- Dividend Yield
- PACB N/A
- KROS N/A
- EPS Growth
- PACB N/A
- KROS N/A
- EPS
- PACB N/A
- KROS 1.57
- Revenue
- PACB $154,584,000.00
- KROS $246,718,000.00
- Revenue This Year
- PACB $6.06
- KROS $6,657.47
- Revenue Next Year
- PACB $15.15
- KROS N/A
- P/E Ratio
- PACB N/A
- KROS $11.04
- Revenue Growth
- PACB N/A
- KROS 37798.31
- 52 Week Low
- PACB $0.85
- KROS $9.12
- 52 Week High
- PACB $2.46
- KROS $72.37
- Technical
- Relative Strength Index (RSI)
- PACB 64.22
- KROS 63.54
- Support Level
- PACB $1.52
- KROS $16.31
- Resistance Level
- PACB $1.91
- KROS $18.42
- Average True Range (ATR)
- PACB 0.19
- KROS 0.81
- MACD
- PACB 0.01
- KROS 0.07
- Stochastic Oscillator
- PACB 97.19
- KROS 68.41
About PACB Pacific Biosciences of California Inc.
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.